Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?

Yuanwei Shi; Danting Tang; Xiaoqi Li; Xiaoli Xie; Yufu Ye; Lijuan Wang

doi:10.3389/fonc.2022.889034

Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?

Front Oncol. 2022 May 23:12:889034. doi: 10.3389/fonc.2022.889034. eCollection 2022.

Authors

Yuanwei Shi^{1

2}, Danting Tang^{1

2}, Xiaoqi Li^{1

2}, Xiaoli Xie², Yufu Ye^{3

4}, Lijuan Wang^{2

5}

Affiliations

¹ School of Clinical Medicine, Weifang Medical University, Weifang, China.
² Central Laboratory, Linyi People's Hospital, Linyi, China.
³ Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
⁴ Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
⁵ Linyi Key Laboratory of Tumor Biology, Linyi, China.

Abstract

The galectin family of proteins has high affinity with β-galactoside-containing glycans. These proteins participate in cell growth and differentiation, cell adhesion, cell signal transduction, cell apoptosis, and other cellular activities. In recent years, a large number of studies have described the expression and correlation of galectins in different tumors. Each member of the family plays a vital role in tumor growth, progression, angiogenesis, adhesion, and tumor immune escape. Studies on the roles of galectins in lymphoma have mainly involved galectin-1, -3, -7, and -9. The results suggest that galectins may become novel targets for precise tumor treatment. This article reviews current research progress regarding galectins in lymphoma and provides new ideas for exploring them as novel targets for treating lymphoma and other important medical issues.

Keywords: galectin-1; galectin-3; galectin-7; galectin-9; lymphoma.

Publication types

Review